Navigation Links
Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
Date:2/27/2013

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Geoff Nichol , M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 6, 2013, at the 33rd Annual Cowen and Company Health Care Conference which will be held in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... RADNOR, Pennsylvania , 22 de marzo de ... proveedor independiente global líder de soluciones de productos ... ha anunciado hoy que ha adquirido EPL Archives, ... apoya a los clientes en todo el ciclo ... y comercialización ofreciendo una muestra de archivo, almacenamiento ...
(Date:3/22/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Respiratory care ... 10.9% over the next decade to reach approximately $38.27 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)...  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... data solutions, today reported financial and operational results ... December 31, 2016. 2016 Highlights ... 241% compared to the full year 2015  ... entire year  Direct-to-consumer model launched ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... 22, 2017 , ... Last year, 43 million gallons of surplus milk was ... While excess dairy can be caused by several factors, one pharmaceutical company CEO ... to properly digest lactose, a sugar found in milk and milk products. ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a ... greater Nassau County region, is embarking on a combined charity effort with the Great ... For the last 25 years, the Great Neck Breast Cancer Coalition has worked to ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... financial planning assistance, and related services to families and business owners in the ... cooperation with the Leukemia & Lymphoma Society. , Every 3 minutes, someone in ...
(Date:3/22/2017)... ... ... The Senior Citizens League (TSCL) is calling on Congressional leadership to ... — including the debt held by the Social Security Trust Fund. “Congressional inaction ... to House and Senate budget leaders. “In prior debates to lift the debt ...
(Date:3/22/2017)... Hills, CA (PRWEB) , ... March 22, 2017 , ... ... 75 should not undergo PSA (prostate-specific antigen) screening, the cancer screening continues to stir ... in 2008 because it found that the risks outweighed the benefits. Now, news ...
Breaking Medicine News(10 mins):